Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged RatsJohn J AlamInternational Journal of Molecular Sciences|August 6, 2020
P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative DiseaseUrsula A Germann, John J AlamPlos One|December 4, 2020
Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein levelJohn J Alam, Michael Krakovsky, Ursula Germann, et al.Alzheimer'S Research & Therapy|May 28, 2021
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's diseaseNiels D Prins, John E Harrison, Hui-May Chu, et al.Neurology|September 1, 2023
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy BodiesJohn J Alam, Paul Maruff, Susan R Doctrow, et al.Plos Computational Biology|January 14, 2012
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infectionBambang S Adiwijaya, Tara L Kieffer, Joshua Henshaw, et al.Nature Communications|September 21, 2022
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degenerationYing Jiang, John J Alam, Stephen N Gomperts, et al.Pageof 1